Market Research Logo

Global Choroidal Neovascularization Market 2016-2020

About Choroidal Neovascularization

Choroidal neovascularization is the formation of new blood vessels in the choroid layer of the eye. These vessels grow through the Bruch membrane into the subretinal space, blocking the proper functioning of retina and leading to vision loss. The condition is often associated with myopia, malignant myopic degeneration, or age-related macular degeneration (AMD).

Technavio’s analysts forecast the global choroidal neovascularization market to grow at a CAGR of 6.64% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global choroidal neovascularization market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of choroidal neovascularization.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Choroidal Neovascularization Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Bayer HealthCare
  • Novartis
  • Regeneron Pharmaceuticals
  • F. Hoffmann-La Roche
Other prominent vendors
  • Alcon
  • Allergan
  • Avalanche
  • Bausch and Lomb
  • Gilead Sciences
  • Iconic Therapeutics
  • Lpath
  • Neurotech Pharmaceuticals
  • Ohr Pharmaceutical
  • Opthea
  • Ophthotech
  • PanOptica
  • Pfizer
  • Promedior
  • QLT
  • Quark
  • Resolvyx Pharmaceuticals
  • RXi Pharmaceuticals
  • Sagent Pharmaceuticals
  • Santen
  • Sanwa Kagaku Kenkyusho
Market driver
  • Growing older population
  • For a full, detailed list, view our report
Market challenge
  • High cost of treatment
  • For a full, detailed list, view our report
Market trend
  • Strategic alliances and M&A
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Choroidal Neovascularization Market 2016-2020

Technavio recognizes the following companies as the key players in the Global Choroidal Neovascularization Market: Bayer HealthCare, Novartis, Regeneron Pharmaceuticals and F. Hoffmann-La Roche.

Other Prominent Vendors in the market are: Alcon, Allergan, Avalanche, Bausch and Lomb, Gilead Sciences, Iconic Therapeutics, Lpath, Neurotech Pharmaceuticals, Ohr Pharmaceutical, Opthea, Ophthotech, PanOptica, Pfizer, Promedior, QLT, Quark, Resolvyx Pharmaceuticals, RXi Pharmaceuticals, Sagent Pharmaceuticals, Santen and Sanwa Kagaku Kenkyusho.

Commenting on the report, an analyst from Technavio’s team said: “The market presents significant growth opportunities for vendors. Companies are increasingly forming strategic alliances and engaging in M&A to increase their market share. As the development cost of ophthalmic drugs is high, small biotechnology firms are forming alliances with big pharmaceutical companies for product development.”

According to the report, Better infrastructure in terms of healthcare facilities and sophisticated treatment options has led to a rise in the life expectancy rates, leading to a rise in the number of people over 60 years. The normal aging process results in reduced choroidal blood flow, which leads to ischemia. This, in turn, leads to increased expression of VEGF and development of excess blood vessels resulting in choroidal neovascularization and finally the loss of vision. With the increase in older population, the demand for choroidal neovascularization drugs is also increasing.

Further, the report states that High cost of treatment restricts the market growth.

Companies Mentioned

Bayer HealthCare, Novartis, Regeneron Pharmaceuticals, F. Hoffmann-La Roche, Alcon, Allergan, Avalanche, Bausch and Lomb, Gilead Sciences, Iconic Therapeutics, Lpath, Neurotech Pharmaceuticals, Ohr Pharmaceutical, Opthea, Ophthotech, PanOptica, Pfizer, Promedior, QLT, Quark, Resolvyx Pharmaceuticals, RXi Pharmaceuticals, Sagent Pharmaceuticals, Santen, Sanwa Kagaku Kenkyusho.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
    • Key buying criteria
      • Table Key buying criteria for choroidal neovascularization drugs
  • Disease overview
    • Introduction
      • Table Types of choroidal neovascularization
    • Pathophysiology
    • Symptoms
      • Table Symptoms of choroidal neovascularization
    • Management
      • Table Treatment options for choroidal neovascularization
    • Epidemiology
  • Product portfolio of approved therapies
  • Pipeline analysis
    • Table Pipeline portfolio: Global choroidal neovascularization therapeutics
    • OHR-102
    • RTH258
    • Fovista
    • RG7716
    • PF-04523655
    • NT-503
    • LFG316
    • REGN2176-3
    • Zimura
    • LHA510
    • DE-120
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global choroidal neovascularization market 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by ROA
    • Table Segmentation of global choroidal neovascularization market by ROA 2015
    • IV
    • Intravitreal
  • Geographical segmentation
    • Global choroidal neovascularization market by geographical segmentation 2015-2020
      • Table Market segmentation by geography 2015
      • Table Choroid neovascularization market revenue by geography 2015-2020 ($ billions)
    • Choroidal neovascularization market in Americas
      • Table Choroidal neovascularization market in Americas 2015-2020 ($ billions)
    • Choroidal neovascularization market in EMEA
      • Table Choroidal neovascularization market in EMEA 2015-2020 ($ billions)
    • Choroidal neovascularization market in APAC
      • Table Choroidal neovascularization market in APAC 2015-2020 ($ millions)
      • Table Global choroidal neovascularization market: YoY growth and revenue based on geography 2015-2020
  • Market drivers
    • Growing older population
    • Increased prevalence of chronic diseases
    • High patient and physician satisfaction
    • Increase in diagnosis rate
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • High cost of treatment
    • Limited public awareness
    • Side effects associated with treatment options
    • Availability of alternative therapies
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Strategic alliances and M&A
    • Increased initiatives and programs
    • Use of combination therapies
    • Increase in R&D
  • Vendor landscape
    • Competitive scenario
    • Market analysis 2015
      • Table Vendor ranking of global choroidal neovascularization market 2015
    • F. Hoffmann-La Roche
      • Table Roche: YoY growth and revenue of Avastin 2011-2014 ($ billions)
      • Table Roche: YoY growth and revenue of Lucentis 2011-2014 ($ billions)
      • Table Roche: Key takeaways
    • Novartis
      • Table Novartis' specialty ophthalmic segmentation by revenue 2014
      • Table Novartis: YoY revenue and growth rate of Lucentis (excluding the US) 2012-2014 ($ millions)
      • Table Novartis: Key takeaways
    • Regeneron Pharmaceuticals
      • Table Regeneron: YoY revenue and growth rate of EYLEA (in the US) 2012-2014 ($ billions)
      • Table Regeneron Pharmaceuticals: Key takeaways
    • Bayer HealthCare
      • Table Bayer HealthCare: YoY revenue and growth rate of EYLEA 2012-2014 ($ millions)
      • Table Bayer HealthCare: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report